Skip to content
Pimavanserin
Nuplazid (pimavanserin) is a small molecule pharmaceutical. Pimavanserin was first approved as Nuplazid on 2016-04-29. It is used to treat hallucinations, parkinson disease, and schizophrenia spectrum and other psychotic disorders in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2A.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
signs and symptoms pathological conditionsD013568
behavior and behavior mechanismsD001520
mental disordersD001523
Trade Name
FDA
EMA
Nuplazid
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pimavanserin tartrate
Tradename
Company
Number
Date
Products
NUPLAZIDAcadia PharmaceuticalsN-207318 RX2018-06-28
1 products, RLD, RS
NUPLAZIDAcadia PharmaceuticalsN-210793 RX2018-06-28
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
nuplazidNew Drug Application2020-11-24
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hallucinationsHP_0000738D006212F06.0
parkinson diseaseEFO_0002508D010300G20
schizophrenia spectrum and other psychotic disordersD019967
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Pimavanserin Tartrate, Nuplazid, Acadia Pharms Inc
104491852038-08-27DP
106464802038-08-27DP
108498912038-08-27DPU-1974
114527212038-08-27DP
105178602037-03-23U-1974
109530002037-03-23U-1974
76017402030-04-29DS, DP
77326152028-06-03DS, DP
76592852026-08-24U-1844
79235642025-09-26DS, DP
86181302024-01-15U-1845
89213932024-01-15U-1846
95662712024-01-15U-1974
100289442024-01-15U-1974
ATC Codes
N: Nervous system drugs
N05: Psycholeptics
N05A: Antipsychotics
N05AX: Other antipsychotics in atc
N05AX17: Pimavanserin
HCPCS
No data
Clinical
Clinical Trials
51 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
XerostomiaD014987K11.712215
Open-angle glaucomaD005902EFO_0004190H40.11113
Angle-closure glaucomaD015812112
AnisocoriaD015875H57.0211
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PresbyopiaD011305H52.4327113
GlaucomaD005901EFO_0000516H40134
Ocular hypertensionD009798EFO_1001069H40.0123
Head and neck neoplasmsD006258133
PseudophakiaD019591112
Dry eye syndromesD015352H04.12112
Breast neoplasmsD001943EFO_0003869C5011
NeoplasmsD009369C8011
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
KeratoconjunctivitisD007637H16.211
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients22
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cystic fibrosisD003550EFO_0000390E8433
Exfoliation syndromeD017889EFO_000423511
Diabetes mellitusD003920EFO_0000400E08-E1311
CataractD002386EFO_0001059H26.911
Chronic kidney failureD007676EFO_0003884N18.611
Postoperative cognitive complicationsD00007969011
DeliriumD003693R41.011
Cognitive dysfunctionD060825G31.8411
MyopiaD009216H52.111
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePIMAVANSERIN
INNpimavanserin
Description
Pimavanserin is a member of the class of ureas in which three of the four hydrogens are replaced by 4-fluorobenzyl, 1-methylpiperidin-4-yl, and 4-(isopropyloxy)benzyl groups. An atypical antipsychotic that is used (in the form of its tartrate salt) for treatment of hallucinations and delusions associated with Parkinson's disease. It has a role as an antipsychotic agent, a 5-hydroxytryptamine 2A receptor inverse agonist and a serotonergic antagonist. It is a member of ureas, a member of piperidines, a member of monofluorobenzenes, an aromatic ether and a tertiary amino compound. It is a conjugate base of a pimavanserin(1+).
Classification
Small molecule
Drug classserotonin 5-HT2 receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1
Identifiers
PDB
CAS-ID706779-91-1
RxCUI1791685
ChEMBL IDCHEMBL2111101
ChEBI ID
PubChem CID10071196
DrugBankDB05316
UNII IDJZ963P0DIK (ChemIDplus, GSRS)
Target
Agency Approved
HTR2A
HTR2A
Organism
Homo sapiens
Gene name
HTR2A
Gene synonyms
HTR2
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 2A
Protein synonyms
5-HT2 receptor, 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled, serotonin 5-HT-2A receptor, Serotonin receptor 2A
Uniprot ID
Mouse ortholog
Htr2a (15558)
5-hydroxytryptamine receptor 2A (P35363)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 736 documents
View more details
Safety
Black-box Warning
Black-box warning for: Nuplazid
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,037 adverse events reported
View more details